LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer

• Main Authors: Wang F, Liang S, Liu X, Han L, Wang J, Du Q
• Format: Article
• Language: English
• Published: Dove Medical Press 2018-10-01
• Series: OncoTargets and Therapy
• Subjects: LINC00460; KDM2A; miR-342-3p; gastric cancer
• Online Access: https://www.dovepress.com/linc00460-modulates-kdm2a-to-promote-cell-proliferation-and-migration--peer-reviewed-article-OTT

Fang Wang,1 Shaobo Liang,2 Xiaowei Liu,1 Lei Han,1 Junye Wang,1 Qin Du1 1Department of Oncology, Affiliated Hospital of Jining Medical College, Jining 272029, China; 2Department of Gastroenterology, Central Hospital of Shanxian County, Heze, 274399, China Background: Increasing evidence has shown that long non-coding RNAs (lncRNAs) play important roles in the occurrence and development of human cancers. LINC00460, a novel tumor-related lncRNA, has been reported to be involved in several types of human malignancies. However, the role of LINC00460 in gastric cancer (GC) is still unclear. The present study aimed at exploring the biological role of LINC00460 in GC and illuminating the potential molecular mechanisms. Methods: In this study, qRT-PCR, western blotting, MTT assay, and Transwell invasion assay were used to conduct relevant experimental analysis. Results: Here, we found that LINC00460 was highly expressed in GC tissues and cell lines. Moreover, LINC00460 over-expression was found to promote GC cell proliferation, migration and invasion, whereas LINC00460 down-regulation significantly inhibited these processes. Notably, we confirmed that LINC00460 could up-regulate KDM2A expression by competitively binding to miR-342-3p in GC cells. Furthermore, the suppressive effects of LINC00460 down-regulation on GC cell proliferation, migration and invasion were partially reversed by a miR-342-3p inhibitor. Conclusion: In summary, our findings provide evidence for LINC00460 as a potential therapeutic target in GC. Keywords: LINC00460, KDM2A, miR-342-3p, gastric cancer